A 52-year-old woman with hypertension is started on a new antihypertensive agent. After 3 weeks, she develops severe headaches, profuse sweating, and palpitations. Her blood pressure is 185/110 mmHg. Serum electrolytes and renal function are normal. On further history, she reports that her symptoms worsen after consuming foods high in tyramine (aged cheese, cured meats). A diagnosis of hypertensive crisis secondary to a drug–nutrient interaction is suspected. The mechanism involves impaired degradation of catecholamines due to inhibition of monoamine oxidase (MAO), leading to excessive activation of α~1~-adrenergic receptors and the IP~3~/DAG second-messenger pathway. What is the most appropriate immediate management?

Explanation

## Clinical Context This patient has **hypertensive crisis triggered by tyramine ingestion in the setting of MAO inhibitor use** (likely phenelzine or tranylcypromine, which are still used for treatment-resistant depression). The mechanism is: 1. **MAO inhibition** → ↓ catecholamine degradation 2. **Tyramine ingestion** → ↑ sympathomimetic effect (tyramine is a substrate for MAO) 3. **Excessive noradrenaline release** → ↑ α~1~-adrenergic receptor activation 4. **IP~3~/DAG pathway activation** → ↑ intracellular Ca^2+^ → smooth muscle contraction → severe hypertension ## Why the Correct Answer is Right **Key Point:** In **acute hypertensive crisis with sympathomimetic excess** (BP >180/110 mmHg with end-organ symptoms), the immediate goal is **rapid vasodilation** using **direct-acting vasodilators**, not sympathetic blockade alone. **High-Yield:** The management hierarchy for hypertensive crisis: - **First-line:** Phentolamine (α-blocker) + sodium nitroprusside (direct vasodilator) - **Rationale:** Phentolamine rapidly blocks α~1~-mediated vasoconstriction; nitroprusside provides titratable, rapid BP reduction - **Discontinue the offending agent** (MAO inhibitor) to prevent ongoing catecholamine accumulation **Clinical Pearl:** ~~Do NOT use β-blockers alone~~ in catecholamine excess. Beta-blockade without alpha-blockade causes **unopposed α-adrenergic vasoconstriction**, paradoxically worsening hypertension. Phentolamine must precede or accompany any β-blocker. ## Why Each Distractor is Wrong | Option | Reason | | --- | --- | | Continue MAO inhibitor + add doxazosin | Doxazosin is a selective α~1~-blocker but is **oral and slow-acting** (onset 1–2 hours). In acute hypertensive crisis (BP 185/110 with symptoms), immediate IV vasodilation is required. Continuing the MAO inhibitor perpetuates the problem. | | Plasma catecholamine levels + labetalol | Labetalol is a combined α/β-blocker but is **slower-acting** than phentolamine + nitroprusside. Measuring catecholamines delays treatment in an acute emergency. Labetalol does not provide the rapid, titratable vasodilation needed. | | Propranolol monotherapy | **Contraindicated.** Pure β-blockade in catecholamine excess causes unopposed α-adrenergic vasoconstriction, worsening hypertension. Propranolol also increases risk of hypertensive encephalopathy and stroke. | ## Management Algorithm ```mermaid flowchart TD A[Hypertensive crisis + tyramine + MAO inhibitor]:::outcome --> B{BP > 180/110 + symptoms?}:::decision B -->|Yes| C[Discontinue MAO inhibitor]:::action C --> D[Phentolamine 5 mg IV bolus]:::action D --> E[Sodium nitroprusside infusion]:::action E --> F[Monitor BP q5-10 min]:::action F --> G[Target BP < 160/100 mmHg]:::outcome B -->|No, stable| H[Oral α-blocker + dietary counselling]:::action ``` ## Mnemonic: MAO Crisis Management **"PANS"** — **P**hentolamine, **A**void β-blockers alone, **N**itroprusside, **S**top MAO inhibitor - **P:** Phentolamine is first-line for α-excess - **A:** Always use α-blocker before β-blocker - **N:** Nitroprusside provides rapid, titratable vasodilation - **S:** Stop the offending agent immediately ## Key Mechanism: IP~3~/DAG Pathway in Hypertensive Crisis α~1~-adrenergic receptor activation (via excessive noradrenaline) triggers: - **PLC activation** → **IP~3~ + DAG** generation - **IP~3~** → ↑ intracellular Ca^2+^ → smooth muscle contraction - **DAG** → PKC activation → further contractility Direct vasodilators (nitroprusside) bypass this pathway by activating guanylate cyclase → ↑cGMP → smooth muscle relaxation, independent of adrenergic signalling.